Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × talazoparib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Prostatic Neoplasms 9 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Endometrial Neoplasms 3 Small Cell Lung Carcinoma 2 Fallopian Tube Neoplasms 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 84 Carboplatin 71 Specimen Handling 67 Pemetrexed 61 Magnetic Resonance Spectroscopy 56 Cisplatin 46 durvalumab 43 Paclitaxel 35 Nivolumab 30 osimertinib 27 atezolizumab 27 Radiosurgery 26 Biopsy 24 Docetaxel 23 Standard of Care 22 Radiotherapy 22 Immunoglobulin G 22 Disulfides 21 Blood Specimen Collection 21 Gemcitabine 19 Radiation 18 Practice Guidelines as Topic 18 Drug Therapy 18 Etoposide 16 Taxes 15 Educational Status 15 X-Rays 13 Bevacizumab 12 130-nm albumin-bound paclitaxel 12 Surveys and Questionnaires 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡